Quantitative magnetic resonance imaging of pulmonary hypertension: A practical approach to the current state of the art

Journal of Thoracic Imaging

Volumn 29, Issue 2, 2014, Pages 68-79

  Swift, Andrew J ^a   Wild, Jim M ^a   Nagle, Scott K ^b,c,d   Roldán Alzate, Alejandro ^b   François, Christopher J ^b   Fain, Sean ^b,d   Johnson, Kevin ^e   Capener, Dave ^a   Van Beek, Edwin J R ^e   Kiely, David G ^e   Wang, Kang ^f   Schiebler, Mark L ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Royal Hammashire Hospital   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f GE HEALTHCARE   (United States)

Author keywords

heart catheterization; magnetic resonance imaging; multidetector computed tomography; pulmonary hypertension; thromboembolism

Indexed keywords

DISEASE PROGRESSION; HUMANS; HYPERTENSION, PULMONARY; LUNG; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; REPRODUCIBILITY OF RESULTS;

EID: 84894421304     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0000000000000079     Document Type: Conference Paper

References (82)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl):S43-S54.
2. Hurdman J, Condliffe R, Elliot CA, et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J. 2012;39:945-955.
3. Kiely DG, Elliot CA, Sabroe I, et al. Pulmonary hypertension: diagnosis and management. BMJ. 2013;346:f2028.
4. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-2537.
5. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115:343-349.
6. Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J Respir Crit Care Med. 2012;186:790-796.
7. Kane GC, Maradit-Kremers H, Slusser JP, et al. Integration of clinical and hemodynamic parameters in the prediction of longterm survival in patients with pulmonary arterial hypertension. Chest. 2011;139:1285-1293.
8. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58:2511-2519.
9. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005;52:3792-3800.
10. Bradlow WM, Hughes ML, Keenan NG, et al. Measuring the heart in pulmonary arterial hypertension (PAH): implications for trial study size. J Magn Reson Imaging. 2010; 31:117-124.
11. Bellenger NG, Davies LC, Francis JM, et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000;2:271-278.
12. Hsiao A, Lustig M, Alley MT, et al. Evaluation of valvular insufficiency and shunts with parallel-imaging compressedsensing 4D phase-contrast MR imaging with stereoscopic 3D velocity-fusion volume-rendered visualization. Radiology. 2012;265:87-95.
13. Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004;147:218-223.
14. Rajaram S, Swift AJ, Capener D, et al. Diagnostic accuracy of contrast-enhanced MR angiography and unenhanced proton MR imaging compared with CT pulmonary angiography in chronic thromboembolic pulmonary hypertension. Eur Radiol. 2012;22:310-317.
15. Schiebler ML, Nagle SK, Francois CJ, et al. Effectiveness of MR angiography for the primary diagnosis of acute pulmonary embolism: clinical outcomes at 3 months and 1 year. J Magn Reson Imaging. 2013;38:914-925.
16. Rajaram S, Swift AJ, Telfer A, et al. 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry. Thorax. 2013;68:677-678.
17. Bradlow WM, Assomull R, Kilner PJ, et al. Understanding late gadolinium enhancement in pulmonary hypertension. Circ Cardiovasc Imaging. 2010;3:501-503.
18. Rajaram S, Swift AJ, Capener D, et al. Lung morphology assessment with balanced steady-state free precession MR imaging compared with CT. Radiology. 2012;263: 569-577.
19. Song HK, Wright AC, Wolf RL, et al. Multislice double inversion pulse sequence for efficient black-blood MRI. Magn Reson Med. 2002;47:616-620.
20. von Schulthess GK, Fisher MR, Higgins CB. Pathologic blood flow in pulmonary vascular disease as shown by gated magnetic resonance imaging. Ann Intern Med. 1985;103:317-323.
21. Frank H, Globits S, Glogar D, et al. Detection and quantification of pulmonary artery hypertension with MR imaging: results in 23 patients. Am J Roentgenol. 1993;161:27-31.
22. Swift AJ, Rajaram S, Marshall H, et al. Black blood MRI has diagnostic and prognostic value in the assessment of patients with pulmonary hypertension. Eur Radiol. 2012;22: 695-702.
23. Pohost GM, Hung L, Doyle M. Clinical use of cardiovascular magnetic resonance. Circulation. 2003;108:647-653.
24. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28:1250-1257.
25. Swift AJ, Rajaram S, Condliffe R, et al. Diagnostic accuracy of cardiovascular magnetic resonance imaging of right ventricular morphology and function in the assessment of suspected pulmonary hypertension results from the ASPIRE registry. J Cardiovasc Magn Reson. 2012;14:40.
26. Vonk-Noordegraaf A, Marcus JT, Gan CT, et al. Interventricular mechanical asynchrony due to right ventricular pressure overload in pulmonary hypertension plays an important role in impaired left ventricular filling. Chest. 2005;128:628S-630S.
27. Beyar R. Heart inefficiency in pulmonary hypertension: a double jeopardy. J Am Coll Cardiol. 2008;51:758-759.
28. Maceira AM, Prasad SK, Khan M, et al. Reference right ventricular systolic and diastolic function normalized to age, gender and body surface area from steady-state free precession cardiovascular magnetic resonance. Eur Heart J. 2006;27:2879-2888.
29. Swift AJ, Rajaram S, Condliffe R, et al. Prognostic value of corrected cardiac magnetic resonance imaging measurements in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2013. [Epub ahead of print].
30. Mauritz GJ, Kind T, Marcus JT, et al. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest. 2012;141: 935-943.
31. Roeleveld RJ, Marcus JT, Faes TJ, et al. Interventricular septal configuration at MR imaging and pulmonary arterial pressure in pulmonary hypertension. Radiology. 2005;234: 710-717.
32. Beyar R, Dong SJ, Smith ER, et al. Ventricular interaction and septal deformation: a model compared with experimental data. Am J Physiol. 1993;265:H2044-H2056.
33. Dellegrottaglie S, Sanz J, Poon M, et al. Pulmonary hypertension: accuracy of detection with left ventricular septal-tofree wall curvature ratio measured at cardiac MR. Radiology. 2007;243:63-69.
34. Lopez-Candales A, Rajagopalan N, Kochar M, et al. Systolic eccentricity index identifies right ventricular dysfunction in pulmonary hypertension. Int J Cardiol. 2008;129:424-426.
35. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol. 2002;39: 1214-1219.
36. Gatehouse PD, Keegan J, Crowe LA, et al. Applications of phase-contrast flow and velocity imaging in cardiovascular MRI. Eur Radiol. 2005;15:2172-2184.
37. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156-163.
38. Hagger D, Condliffe R, Woodhouse N, et al. Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology. 2009;48:1137-1142.
39. Mooij CF, de Wit CJ, Graham DA, et al. Reproducibility of MRI measurements of right ventricular size and function in patients with normal and dilated ventricles. J Magn Reson Imaging. 2008;28:67-73.
40. Sanz J, Kuschnir P, Rius T, et al. Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging. Radiology. 2007;243:70-79.
41. Mousseaux E, Tasu JP, Jolivet O, et al. Pulmonary arterial resistance: noninvasive measurement with indexes of pulmonary flow estimated at velocity-encoded MR imaging- preliminary experience. Radiology. 1999;212:896-902.
42. Helderman F, Mauritz GJ, Andringa KE, et al. Early onset of retrograde flow in the main pulmonary artery is a characteristic of pulmonary arterial hypertension. J Magn Reson Imaging. 2011;33:1362-1368.
43. Sanz J, Kariisa M, Dellegrottaglie S, et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2:286-295.
44. Sanz J, Dellegrottaglie S, Kariisa M, et al. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. Am J Cardiol. 2007;100: 731-735.
45. Nogami M, Ohno Y, Koyama H, et al. Utility of phase contrast MR imaging for assessment of pulmonary flow and pressure estimation in patients with pulmonary hypertension: comparison with right heart catheterization and echocardiography. J Magn Reson Imaging. 2009;30:973-980.
46. Swift AJ, Rajaram S, Condliffe R, et al. Pulmonary artery relative area change detects mild elevations in pulmonary vascular resistance and predicts adverse outcome in pulmonary hypertension. Invest Radiol. 2012;47:571-577.
47. Gan CT, Lankhaar JW, Westerhof N, et al. Noninvasively assessed pulmonary artery stiffness predicts mortality in pulmonary arterial hypertension. Chest. 2007;132:1906-1912.
48. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-1327.
49. Messroghli DR, Walters K, Plein S, et al. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Magn Reson Med. 2007;58:34-40.
50. Bogaert J DS, Dymarkowski S. Delayed contrast-enhanced MRI: use in myocardial viability assessment and other cardiac pathology. European Radiology.15(suppl 2):; 2005:B52-B58.
51. Teraoka K, Hirano M, Ookubo H, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging. 2004;22:155-161.
52. Blyth KG, Groenning BA, Martin TN, et al. Contrast enhanced- cardiovascular magnetic resonance imaging in patients with pulmonary hypertension. Eur Heart J. 2005;26: 1993-1999.
53. Bradlow WM, Assomull R, Kilner PJ, et al. Understanding late gadolinium enhancement in pulmonary hypertension. Circ Cardiovasc Imaging. 2010;3:501-503.
54. Freed BH, Mardi G-M, Chandra S, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012;14:11.
55. Fink C, Puderbach M, Ley S, et al. Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels. Invest Radiol. 2004;39: 143-148.
56. Chae EJ, Seo JB, Jang YM, et al. Dual-energy CT for assessment of the severity of acute pulmonary embolism: pulmonary perfusion defect score compared with CT angiographic obstruction score and right ventricular/left ventricular diameter ratio. Am J Roentgenol. 2010;194:604-610.
57. Ohno Y, Hatabu H, Murase K, et al. Primary pulmonary hypertension: 3D dynamic perfusion MRI for quantitative analysis of regional pulmonary perfusion. Am J Roentgenol. 2007;188:48-56.
58. Wang K, Busse RF, Holmes JH, et al. Interleaved variable density sampling with a constrained parallel imaging reconstruction for dynamic contrast-enhanced MR angiography. Magn Reson Med. 2011;66:428-436.
59. Wang K, Schiebler ML, Francois CJ, et al. Pulmonary perfusion MRI using interleaved variable density sampling and HighlY constrained cartesian reconstruction (HYCR). J Magn Reson Imaging. 2013;38:751-756.
60. Riederer SJ, Tasciyan T, Farzaneh F, et al. MR fluoroscopy: technical feasibility. Magn Reson Med. 1988;8:1-15.
61. Ohno Y, Murase K, Higashino T, et al. Assessment of bolus injection protocol with appropriate concentration for quantitative assessment of pulmonary perfusion by dynamic contrastenhanced MR imaging. J Magn Reson Imaging. 2007;25:55-65.
62. Risse F, Semmler W, Kauczor HU, et al. Dual-bolus approach to quantitative measurement of pulmonary perfusion by contrastenhanced MRI. J Magn Res Imaging. 2006;24:1284-1290.
63. Ohno Y, Koyama H, Nogami M, et al. Dynamic perfusionMRI: capability for evaluation of disease severity and progression of pulmonary arterial hypertension in patients with connective tissue disease. J Magn Reson Imaging. 2008;28:887-899.
64. Shors SM, Cotts WG, Pavlovic-Surjancev B, et al. Heart failure: evaluation of cardiopulmonary transit times with timeresolved MR angiography. Radiology. 2003;229:743-748.
65. Skrok J, Shehata ML, Mathai S, et al. Pulmonary arterial hypertension: MR imaging-derived first-pass bolus kinetic parameters are biomarkers for pulmonary hemodynamics, cardiac function, and ventricular remodeling. Radiology. 2012;263:678-687.
66. Swift AJ, Telfer A, Rajaram S, et al. Dynamic contrast enhanced magnetic resonance imaging in patients with pulmonary hypertension. Pulm Circ. 2013. (In press).
67. Bradlow WM, Gatehouse PD, Hughes RL, et al. Assessing normal pulse wave velocity in the proximal pulmonary arteries using transit time: a feasibility, repeatability, and observer reproducibility study by cardiovascular magnetic resonance. J Magn Reson Imaging. 2007;25:974-981.
68. Westerhof N, Lankhaar JW, Westerhof BE. The arterial Windkessel. Med Biol Eng Comput. 2009;47:131-141.
69. Reiter G, Reiter U, Kovacs G, et al. Magnetic resonancederived 3-dimensional blood flow patterns in the main pulmonary artery as a marker of pulmonary hypertension and a measure of elevated mean pulmonary arterial pressure. Circ Cardiovasc Imaging. 2008;1:23-30.
70. Truong U, Fonseca B, Dunning J, et al. Wall shear stress measured by phase contrast cardiovascular magnetic resonance in children and adolescents with pulmonary arterial hypertension. J Cardiovasc Magn Reson. 2013;15:81.
71. Schwartz GG, Steinman SK, Weiner MW, et al. In vivo 31PNMR spectroscopy of right ventricle in pigs. Am J Physiol. 1992;262(pt 2):H1950-H1954.
72. Bradlow WM, Gibbs JS, Mohiaddin RH. Cardiovascular magnetic resonance in pulmonary hypertension. J Cardiovasc Magn Reson. 2012;14:6.
73. Swift AJ, Rajaram S, Hurdman J, et al. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry. JACC Cardiovasc Imaging. 2013;6:1036-1047.
74. Paelinck BP, de Roos A, Bax JJ, et al. Feasibility of tissue magnetic resonance imaging: a pilot study in comparison with tissue Doppler imaging and invasive measurement. J Am Coll Cardiol. 2005;45:1109-1116.
75. Moral S, Fernandez-Friera L, Stevens G, et al. New index alpha improves detection of pulmonary hypertension in comparison with other cardiac magnetic resonance indices. Int J Cardiol. 2012;161:25-30.
76. Roeleveld RJ, Marcus JT, Boonstra A, et al. A comparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. J Magn Reson Imaging. 2005;22:67-72.
77. Garcia-Alvarez A, Fernandez-Friera L, Mirelis JG, et al. Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance. Eur Heart J. 2011;32: 2438-2445.
78. Garcia-Alvarez A, Fernandez-Friera L, Garcia-Ruiz JM, et al. Noninvasive monitoring of serial changes in pulmonary vascular resistance and acute vasodilator testing using cardiac magnetic resonance. J Am Coll Cardiol. 2013;62:1621-1631.
79. Sandoval J, Bauerle O, Palomar A, et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation. 1994;89:1733-1744.
80. Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004;147:218-223.
81. Hagger D, Condliffe R, Woodhouse N, et al. Ventricular mass index correlates with pulmonary artery pressure and predicts survival in suspected systemic sclerosis-associated pulmonary arterial hypertension. Rheumatology (Oxford). 2009;48: 1137-1142.
82. Rajaram S, Swift AJ, Capener D, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. J Rheumatol. 2012;39: 1265-1274.